期刊
REC-INTERVENTIONAL CARDIOLOGY
卷 5, 期 2, 页码 110-117出版社
PERMANYER PUBL
DOI: 10.24875/RECICE.M22000353
关键词
Coronary artery disease; Percutaneous coronary intervention; Inflammation; Colchicine
This meta-analysis found that adding colchicine to standard medical therapy in patients undergoing PCI did not reduce overall mortality, cardiovascular mortality, or the risk of urgent revascularization. However, it showed a trend towards a lower risk of myocardial infarction and a significantly lower risk of stroke.
Introduction and objectives: The role of inflammation in the pathogenesis of coronary artery disease, and that resulting from percutaneous coronary intervention (PCI) is increasingly recognized, yet the effect of colchicine in attenuating peri-PCI inflammation remains unknown. This meta-analysis investigated the efficacy of colchicine in patients undergoing PCI for secondary prevention of coronary artery disease. Methods: The Web of Science, PubMed, Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials and ClinicalTrials. gov databases were searched. Data on studies assessing the efficacy profile of colchicine in patients undergoing PCI were pooled using a random-effects model. Results: In 13 studies of 7414 patients, no differences were observed between patients treated with colchicine compared to those without for all-cause mortality (OR, 1.1; 95% CI, 0.72-1.56; I-2 = 0%), cardiovascular mortality (OR, 0.98; 95%CI, 0.42-2.28; I-2 = 14.2%), myocardial infarction (OR, 0.84; 95%CI, 0.65-1.08; I-2 = 1.4%) or coronary revascularization (OR, 0.64; 95%CI, 0.28-1.42; I-2 = 49.3%). However, patients treated with colchicine had a lower risk of stroke (OR, 0.33; 95%CI, 0.15-0.72; I-2 = 0%). Conclusions: Adding colchicine to standard medical therapy in patients undergoing PCI did not decrease all-cause mortality, cardiovascular mortality or urgent revascularization. However, it showed a trend towards a lower risk of myocardial infarction and a significantly lower risk of stroke.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据